A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16048-

  Everson, Elizabeth M ^a   Olzsko, Miles E ^a   Leap, David J ^a   Hocum, Jonah D ^a   Trobridge, Grant D ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOAMY VIRUS VECTOR; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; FOAMY RETROVIRAL VECTOR; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CLONE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE CASSETTE; GENOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; SCID MOUSE; SPLEEN FOCUS FORMING VIRUS; TRANSCRIPTION INITIATION SITE; TRANSGENE; ANIMAL MODEL; ANIMAL TISSUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN GENOME; IN VIVO STUDY; INTERMETHOD COMPARISON; STEM CELL GENE THERAPY; UMBILICAL CORD BLOOD CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 84989263998     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.48     Document Type: Article

References (64)

1. 1 Mukherjee, S, Thrasher, AJ, Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525 (2013), 174–181.
2. 2 Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360 (2009), 447–458.
3. 3 Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Zhang, F, Adams, S, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 3, 2011, 97ra80.
4. 4 Candotti, F, Shaw, KL, Muul, L, Carbonaro, D, Sokolic, R, Choi, C, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120 (2012), 3635–3646.
5. 5 Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003), 415–419.
6. 6 Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003), 255–256.
7. 7 Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008), 3132–3142.
8. 8 Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118 (2008), 3143–3150.
9. 9 Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363 (2010), 1918–1927.
10. 10 Hematti, P, Hong, BK, Ferguson, C, Adler, R, Hanawa, H, Sellers, S, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol, 2, 2004, e423.
11. 11 Laufs, S, Nagy, KZ, Giordano, FA, Hotz-Wagenblatt, A, Zeller, WJ, Fruehauf, S, Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 10 (2004), 874–881.
12. 12 Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24 (2006), 687–696.
13. 13 Cattoglio, C, Facchini, G, Sartori, D, Antonelli, A, Miccio, A, Cassani, B, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110 (2007), 1770–1778.
14. 14 Beard, BC, Dickerson, D, Beebe, K, Gooch, C, Fletcher, J, Okbinoglu, T, et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15 (2007), 1356–1365.
15. 15 Beard, BC, Keyser, KA, Trobridge, GD, Peterson, LJ, Miller, DG, Jacobs, M, et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther 18 (2007), 423–434.
16. 16 Hendrie, PC, Huo, Y, Stolitenko, RB, Russell, DW, A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Ther 16 (2008), 534–540.
17. 17 Hai, M, Adler, RL, Bauer, TR Jr, Tuschong, LM, Gu, YC, Wu, X, et al. Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy. Gene Ther 15 (2008), 1067–1071.
18. 18 Li, CL, Xiong, D, Stamatoyannopoulos, G, Emery, DW, Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 17 (2009), 716–724.
19. 19 Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119 (2009), 964–975.
20. 20 Kustikova, OS, Schiedlmeier, B, Brugman, MH, Stahlhut, M, Bartels, S, Li, Z, et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17 (2009), 1537–1547.
21. 21 Sellers, S, Gomes, TJ, Larochelle, A, Lopez, R, Adler, R, Krouse, A, et al. Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Mol Ther 18 (2010), 1633–1639.
22. 22 Liu, M, Li, CL, Stamatoyannopoulos, G, Dorschner, MO, Humbert, R, Stamatoyannopoulos, JA, et al. Gammaretroviral vector integration occurs overwhelmingly within and near DNase hypersensitive sites. Hum Gene Ther 23 (2012), 231–237.
23. 23 Cornils, K, Bartholomae, CC, Thielecke, L, Lange, C, Arens, A, Glauche, I, et al. Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a ?-retroviral LTR vector. Exp Hematol 41 (2013), 28–38.e3.
24. 24 Nowrouzi, A, Glimm, H, von Kalle, C, Schmidt, M, Retroviral vectors: post entry events and genomic alterations. Viruses 3 (2011), 429–455.
25. 25 Nienhuis, AW, Dunbar, CE, Sorrentino, BP, Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13 (2006), 1031–1049.
26. 26 Enssle, J, Trobridge, GD, Keyser, KA, Ironside, C, Beard, BC, Kiem, HP, Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentiviral vectors. Hum Gene Ther 21 (2010), 397–403.
27. 27 Biffi, A, Bartolomae, CC, Cesana, D, Cartier, N, Aubourg, P, Ranzani, M, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117 (2011), 5332–5339.
28. 28 Cesana, D, Sgualdino, J, Rudilosso, L, Merella, S, Naldini, L, Montini, E, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122 (2012), 1667–1676.
29. 29 Moiani, A, Paleari, Y, Sartori, D, Mezzadra, R, Miccio, A, Cattoglio, C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122 (2012), 1653–1666.
30. 30 Cesana, D, Ranzani, M, Volpin, M, Bartholomae, C, Duros, C, Artus, A, et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 22 (2014), 774–785.
31. 31 Trobridge, GD, Miller, DG, Jacobs, MA, Allen, JM, Kiem, HP, Kaul, R, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103 (2006), 1498–1503.
32. 32 Ohmine, K, Li, Y, Bauer, TR Jr, Hickstein, DD, Russell, DW, Tracking of specific integrant clones in dogs treated with foamy virus vectors. Hum Gene Ther 22 (2011), 217–224.
33. 33 Trobridge, GD, Horn, PA, Beard, BC, Kiem, HP, Large animal models for foamy virus vector gene therapy. Viruses 4 (2012), 3572–3588.
34. 34 Nasimuzzaman, M, Kim, YS, Wang, YD, Persons, DA, High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells. Mol Ther Methods Clin Dev, 1, 2014, 14020.
35. 35 Olszko, ME, Adair, JE, Linde, I, Rae, DT, Trobridge, P, Hocum, JD, et al. Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Ther 22 (2015), 591–595.
36. 36 Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, et al. Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467 (2010), 318–322.
37. 37 Russell, DW, Miller, AD, Foamy virus vectors. J Virol 70 (1996), 217–222.
38. 38 Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J, Russell, DW, Improved foamy virus vectors with minimal viral sequences. Mol Ther 6 (2002), 321–328.
39. 39 Browning, DL, Collins, CP, Hocum, JD, Leap, D, Rae, DT, Trobridge, GD, Insulated foamy viral vectors. Hum Gene Ther, 2015 (e-pub ahead of print).
40. 40 Rae, DT, Collins, CP, Hocum, JD, Browning, DL, Trobridge, GD, Modified genomic sequencing PCR using the MiSeq platform to identify retroviral integration sites. Hum Gene Ther Methods 26 (2015), 221–227.
41. 41 Hocum, JD, Battrell, LR, Maynard, R, Adair, JE, Beard, BC, Rawlings, DJ, et al. VISA–Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing. BMC Bioinformatics, 16, 2015, 212.
42. 42 da Huang, W, Sherman, BT, Lempicki, RA, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4 (2009), 44–57.
43. 43 da Huang, W, Sherman, BT, Lempicki, RA, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37 (2009), 1–13.
44. 44 An, O, Pendino, V, Ratti, E, Gentilini, M, Ciccarelli, FD, NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford), bau015, 2014.
45. 45 Wu, X, Luke, BT, Burgess, SM, Redefining the common insertion site. Virology 344 (2006), 292–295.
46. 46 Trobridge, GD, Wu, RA, Beard, BC, Chiu, SY, Muñoz, NM, von Laer, D, et al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS ONE, 4, 2009, e7693.
47. 47 Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308 (2005), 1171–1174.
48. 48 Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17 (2009), 1919–1928.
49. 49 Kustikova, O, Brugman, M, Baum, C, The genomic risk of somatic gene therapy. Elsevier 20 (2010), 269–278.
50. 50 Fehse, B, Roeder, I, Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 15 (2008), 143–153.
51. 51 Haemmerle, R, Phaltane, R, Rothe, M, Schroder, S, Schambach, A, Moritz, T, Clonal dominance with retroviral insertions near the ANGPT1 and ANGPT2 genes in a human xenotransplant model. Mol Ther, 3, 2014, e200.
52. 52 Watkins, NA, Gusnanto, A, de Bono, B, De, S, Miranda-Saavedra, D, Hardie, DL, et al., Bloodomics Consortium, A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 113 (2009), e1–e9.
53. 53 Scharenberg, MA, Chiquet-Ehrismann, R, Asparuhova, MB, Megakaryoblastic leukemia protein-1 (MKL1): Increasing evidence for an involvement in cancer progression and metastasis. Int J Biochem Cell Biol 42 (2010), 1911–1914.
54. 54 Record, J, Malinova, D, Zenner, HL, Plagnol, V, Nowak, K, Syed, F, et al. Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1. Blood 126 (2015), 1527–1535.
55. 55 Slattery, ML, Lundgreen, A, Herrick, JS, Wolff, RK, Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res 706 (2011), 13–20.
56. 56 Fernández-Medarde, A, Santos, E, Ras in cancer and developmental diseases. Genes Cancer 2 (2011), 344–358.
57. 57 Naoe, T, Kiyoi, H, Normal and oncogenic FLT3. Cell Mol Life Sci 61 (2004), 2932–2938.
58. 58 Levis, M, Small, D, FLT3: ITDoes matter in leukemia. Leukemia 17 (2003), 1738–1752.
59. 59 Barron, DA, Kagey, JD, The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med, 3, 2014, 25.
60. 60 Maldarelli, F, Wu, X, Su, L, Simonetti, FR, Shao, W, Hill, S, Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345 (2014), 179–183.
61. 61 Leboulch, P, Five year outcome of lentiviral gene therapy for human beta-thalassemia, lessons and prospects. Thalassemia Reports, 3, 2013, 43.
62. 62 Siler, U, Paruzynski, A, Holtgreve-Grez, H, Kuzmenko, E, Koehl, U, Renner, ED, et al. Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD - importance of timing. Curr Gene Ther 15 (2015), 416–427.
63. 63 Torres, IO, Kuchenbecker, KM, Nnadi, CI, Fletterick, RJ, Kelly, MJ, Fujimori, DG, Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism. Nat Commun, 6, 2015, 6204.
64. 64 Zhou, S, Mody, D, DeRavin, SS, Hauer, J, Lu, T, Ma, Z, et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 116 (2010), 900–908.